Clinical Holds

The FDA has lifted the partial clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) studies evaluating magrolimab combined with azacitidine.  The FDA removed the partial clinical hold after reviewing the comprehensive safety data from each trial. The company can...

The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO) AlloCAR T trials in response to an abnormality that could theoretically cause cancer. Related: Allogene's BCMA-...

The FDA has lifted the clinical hold on Rocket Pharmaceuticals Inc's (NASDAQ: RCKT) Phase 1 trial of RP-A501 (gene therapy) for Danon Disease, allowing patient enrollment to resume.  The hold was removed after the Company addressed the FDA's requests to modify the...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by nearly 25 percent to $34.50 ahead of Wednesday's market open. The biopharma company focused on the treatment of cancer announced after Tuesday's market close that the U.S. Food and Drug Administration removed a clinical hold...